GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (WBO:BSXC) » Definitions » Cyclically Adjusted PS Ratio

Boston Scientific (WBO:BSXC) Cyclically Adjusted PS Ratio : 9.22 (As of Apr. 27, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Boston Scientific Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Boston Scientific's current share price is €69.00. Boston Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €7.48. Boston Scientific's Cyclically Adjusted PS Ratio for today is 9.22.

The historical rank and industry rank for Boston Scientific's Cyclically Adjusted PS Ratio or its related term are showing as below:

WBO:BSXC' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.22   Med: 5.21   Max: 8.67
Current: 8.67

During the past years, Boston Scientific's highest Cyclically Adjusted PS Ratio was 8.67. The lowest was 1.22. And the median was 5.21.

WBO:BSXC's Cyclically Adjusted PS Ratio is ranked worse than
83.62% of 464 companies
in the Medical Devices & Instruments industry
Industry Median: 2.135 vs WBO:BSXC: 8.67

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Boston Scientific's adjusted revenue per share data for the three months ended in Dec. 2023 was €2.313. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €7.48 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Boston Scientific Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Boston Scientific's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Cyclically Adjusted PS Ratio Chart

Boston Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.12 5.51 5.89 5.86 6.85

Boston Scientific Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.18 6.55 6.29 6.85 -

Competitive Comparison of Boston Scientific's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Boston Scientific's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Cyclically Adjusted PS Ratio falls into.



Boston Scientific Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Boston Scientific's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=69.00/7.48
=9.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Boston Scientific's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.313/129.4194*129.4194
=2.313

Current CPI (Dec. 2023) = 129.4194.

Boston Scientific Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.951 99.695 1.235
201406 1.025 100.560 1.319
201409 1.063 100.428 1.370
201412 1.154 99.070 1.508
201503 1.225 99.621 1.591
201506 1.206 100.684 1.550
201509 1.252 100.392 1.614
201512 1.349 99.792 1.749
201603 1.287 100.470 1.658
201606 1.394 101.688 1.774
201609 1.359 101.861 1.727
201612 1.501 101.863 1.907
201703 1.453 102.862 1.828
201706 1.444 103.349 1.808
201709 1.337 104.136 1.662
201712 1.458 104.011 1.814
201803 1.381 105.290 1.697
201806 1.524 106.317 1.855
201809 1.461 106.507 1.775
201812 1.601 105.998 1.955
201903 1.567 107.251 1.891
201906 1.653 108.070 1.980
201909 1.741 108.329 2.080
201912 1.849 108.420 2.207
202003 1.628 108.902 1.935
202006 1.261 108.767 1.500
202009 1.578 109.815 1.860
202012 1.560 109.897 1.837
202103 1.616 111.754 1.871
202106 1.783 114.631 2.013
202109 1.736 115.734 1.941
202112 1.927 117.630 2.120
202203 1.910 121.301 2.038
202206 2.134 125.017 2.209
202209 2.223 125.227 2.297
202212 2.121 125.222 2.192
202303 2.189 127.348 2.225
202306 2.281 128.729 2.293
202309 2.241 129.860 2.233
202312 2.313 129.419 2.313

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Boston Scientific  (WBO:BSXC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Boston Scientific Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific (WBO:BSXC) Business Description

Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Boston Scientific (WBO:BSXC) Headlines

No Headlines